Catena News
Most Popular Catena Story
Santhera investors bail after lead drug fails PhIII
Switzerland's Santhera Pharmaceuticals (SANN) says its lead drug failed a late-stage trial. And the news triggered a sharp, 31 percent drop in the developer's stock. Even though CEO Klaus Schollmeier Read more...
Latest Headlines
- July 6, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
